{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:07:33Z","timestamp":1792670853840,"version":"4.5.0"},"reference-count":199,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.bcp.2017.01.017","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T19:16:13Z","timestamp":1485890173000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases"],"prefix":"10.1016","volume":"131","author":[{"given":"Chiara","family":"Giacomelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1086\/302269","article-title":"Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold","volume":"64","author":"Paulson","year":"1999","journal-title":"Am. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jnc.13772","article-title":"Pathogenic mechanisms of prion protein, amyloid-\u03b2 and \u03b1-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers","volume":"139","author":"Ugalde","year":"2016","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.017_b0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1582-4934.2010.01010.x","article-title":"Basic mechanisms of neurodegeneration: a critical update","volume":"14","author":"Jellinger","year":"2010","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0020","doi-asserted-by":"crossref","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","article-title":"100 years of Lewy pathology","volume":"9","author":"Goedert","year":"2013","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/alzrt109","article-title":"Examining the mechanisms that link \u03b2-amyloid and \u03b1-synuclein pathologies","volume":"4","author":"Marsh","year":"2012","journal-title":"Alzheimers Res. Ther."},{"issue":"10","key":"10.1016\/j.bcp.2017.01.017_b0035","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.biopsych.2014.12.019","article-title":"Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies","volume":"78","author":"Sengupta","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.bcp.2017.01.017_b0040","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12031-016-0829-1","article-title":"Interactions between \u03b1-synuclein and tau protein: implications to neurodegenerative disorders","volume":"60","author":"Li","year":"2016","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.bcp.2017.01.017_b0045","article-title":"Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting","author":"Kell","year":"2016","journal-title":"Prog. Biophys. Mol. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.017_b0050","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s12035-014-8818-2","article-title":"\u0391-synuclein misfolding versus aggregation relevance to parkinson's disease: critical assessment and modeling","volume":"51","author":"Berrocal","year":"2015","journal-title":"Mol. Neurobiol."},{"issue":"19 Pt A","key":"10.1016\/j.bcp.2017.01.017_b0055","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1016\/j.febslet.2015.07.013","article-title":"Structural, morphological, and functional diversity of amyloid oligomers","volume":"589","author":"Breydo","year":"2015","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2017.01.017_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mad.2016.03.001","article-title":"Structural studies on the mechanism of protein aggregation in age related neurodegenerative diseases","volume":"156","author":"Eftekharzadeh","year":"2016","journal-title":"Mech. Ageing Dev."},{"issue":"8","key":"10.1016\/j.bcp.2017.01.017_b0065","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024083","article-title":"Molecular structure of aggregated amyloid-\u03b2: insights from solid-state nuclear magnetic resonance","volume":"6","author":"Tycko","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrn1007","article-title":"Unfolding the role of protein misfolding in neurodegenerative diseases","volume":"4","author":"Soto","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2017.01.017_b0075","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fnmol.2014.00070","article-title":"The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution","volume":"7","author":"Dantuma","year":"2014","journal-title":"Front. Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0080","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1474-4422(07)70076-5","article-title":"Autophagy and neurodegeneration: when the cleaning crew goes on strike","volume":"6","author":"Martinez-Vicente","year":"2007","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.bcp.2017.01.017_b0085","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1021\/ar300282r","article-title":"Molecular structures of amyloid and prion fibrils: consensus versus controversy","volume":"46","author":"Tycko","year":"2013","journal-title":"Acc. Chem. Res."},{"issue":"16","key":"10.1016\/j.bcp.2017.01.017_b0090","doi-asserted-by":"crossref","first-page":"E1994","DOI":"10.1073\/pnas.1421204112","article-title":"Structural characterization of toxic oligomers that are kinetically trapped during \u03b1-synuclein fibril formation","volume":"112","author":"Chen","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5","key":"10.1016\/j.bcp.2017.01.017_b0095","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/1531-8249(200005)47:5<632::AID-ANA11>3.0.CO;2-N","article-title":"Alpha-synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo","volume":"47","author":"Forloni","year":"2000","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.bcp.2017.01.017_b0100","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1021\/cn4002208","article-title":"P53 functional inhibitors behaving like pifithrin-\u03b2 counteract the Alzheimer peptide non-\u03b2-amyloid component effects in human SH-SY5Y cells","volume":"5","author":"Da Pozzo","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bcp.2017.01.017_b0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fneur.2013.00083","article-title":"The importance of tau phosphorylation for neurodegenerative diseases","volume":"4","author":"Noble","year":"2013","journal-title":"Front. Neurol."},{"issue":"32","key":"10.1016\/j.bcp.2017.01.017_b0110","doi-asserted-by":"crossref","first-page":"24977","DOI":"10.1074\/jbc.M000808200","article-title":"Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly","volume":"275","author":"Evans","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2017.01.017_b0115","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1517\/17460441.2011.586690","article-title":"Advances in tau-based drug discovery","volume":"6","author":"Noble","year":"2011","journal-title":"Expert Opin. Drug Discov."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0120","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1042\/BST20120134","article-title":"Tau oligomers and tau toxicity in neurodegenerative disease","volume":"40","author":"Ward","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bcp.2017.01.017_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2014.00001","article-title":"\u201cTau oligomers,\u201d what we know and what we don't know","volume":"5","author":"Sahara","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.bcp.2017.01.017_b0130","doi-asserted-by":"crossref","first-page":"19393","DOI":"10.1038\/srep19393","article-title":"Extracellular tau oligomers produce an immediate impairment of LTP and memory","volume":"6","author":"F\u00e1","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2017.01.017_b0135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.neuro.26.010302.081142","article-title":"Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders","volume":"26","author":"Caughey","year":"2003","journal-title":"Annu. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0140","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.3892\/mmr.2016.4948","article-title":"Role of neuroinflammation in neurodegenerative diseases (Review)","volume":"13","author":"Chen","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0145","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5607\/en.2015.24.4.325","article-title":"The role of oxidative stress in neurodegenerative diseases","volume":"24","author":"Kim","year":"2015","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.bcp.2017.01.017_b0150","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12916-014-0206-2","article-title":"The overlap between vascular disease and Alzheimer's disease\u2013lessons from pathology","volume":"12","author":"Attems","year":"2014","journal-title":"BMC Med."},{"key":"10.1016\/j.bcp.2017.01.017_b0155","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pneurobio.2013.10.004","article-title":"Autophagy and apoptosis dysfunction in neurodegenerative disorders","volume":"112","author":"Ghavami","year":"2014","journal-title":"Prog. Neurobiol."},{"issue":"19","key":"10.1016\/j.bcp.2017.01.017_b0160","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.2174\/15680266113136660173","article-title":"Therapy in prion diseases","volume":"13","author":"Forloni","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2017.01.017_b0165","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/mds.26624","article-title":"Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases","volume":"31","author":"Forloni","year":"2016","journal-title":"Mov. Disord."},{"issue":"5619","key":"10.1016\/j.bcp.2017.01.017_b0170","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1126\/science.1082324","article-title":"Initiation and synergistic fibrillization of tau and alpha-synuclein","volume":"300","author":"Giasson","year":"2003","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bcp.2017.01.017_b0175","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.tins.2004.01.007","article-title":"More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases","volume":"27","author":"Lee","year":"2004","journal-title":"Trends Neurosci."},{"issue":"21","key":"10.1016\/j.bcp.2017.01.017_b0180","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline","volume":"30","author":"Clinton","year":"2010","journal-title":"J. Neurosci."},{"issue":"21","key":"10.1016\/j.bcp.2017.01.017_b0185","doi-asserted-by":"crossref","first-page":"12245","DOI":"10.1073\/pnas.211412398","article-title":"Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease","volume":"98","author":"Masliah","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5","key":"10.1016\/j.bcp.2017.01.017_b0190","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0002-9440(10)65722-7","article-title":"Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes","volume":"153","author":"Lippa","year":"1998","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.bcp.2017.01.017_b0195","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0002-9440(10)61119-4","article-title":"Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam","volume":"160","author":"Forman","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2017.01.017_b0200","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1750-1326-9-43","article-title":"Alpha-synuclein and tau: teammates in neurodegeneration?","volume":"9","author":"Moussaud","year":"2014","journal-title":"Mol. Neurodegener."},{"issue":"30","key":"10.1016\/j.bcp.2017.01.017_b0205","doi-asserted-by":"crossref","first-page":"10253","DOI":"10.1523\/JNEUROSCI.0581-12.2012","article-title":"Soluble \u03b1-synuclein is a novel modulator of Alzheimer's disease pathophysiology","volume":"32","author":"Larson","year":"2012","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.bcp.2017.01.017_b0210","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0197-4580(02)00123-9","article-title":"Emerging Alzheimer's disease therapies: focusing on the future","volume":"23","author":"Trojanowski","year":"2002","journal-title":"Neurobiol. Aging"},{"issue":"9","key":"10.1016\/j.bcp.2017.01.017_b0215","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s11064-006-9140-9","article-title":"Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease","volume":"31","author":"Mandal","year":"2006","journal-title":"Neurochem. Res."},{"issue":"9","key":"10.1016\/j.bcp.2017.01.017_b0220","doi-asserted-by":"crossref","first-page":"e3135","DOI":"10.1371\/journal.pone.0003135","article-title":"Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases","volume":"3","author":"Tsigelny","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2017.01.017_b0225","doi-asserted-by":"crossref","first-page":"780179","DOI":"10.1155\/2014\/780179","article-title":"Mitochondrial dysfunction: different routes to Alzheimer's disease therapy","volume":"2014","author":"Picone","year":"2014","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"41","key":"10.1016\/j.bcp.2017.01.017_b0230","doi-asserted-by":"crossref","first-page":"26292","DOI":"10.1074\/jbc.273.41.26292","article-title":"Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation","volume":"273","author":"Jensen","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"6106","key":"10.1016\/j.bcp.2017.01.017_b0235","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/325733a0","article-title":"The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor","volume":"325","author":"Kang","year":"1987","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bcp.2017.01.017_b0240","doi-asserted-by":"crossref","first-page":"e26609","DOI":"10.1371\/journal.pone.0026609","article-title":"Tau enhances \u03b1-synuclein aggregation and toxicity in cellular models of synucleinopathy","volume":"6","author":"Badiola","year":"2011","journal-title":"PLoS ONE"},{"issue":"36","key":"10.1016\/j.bcp.2017.01.017_b0245","doi-asserted-by":"crossref","first-page":"25481","DOI":"10.1074\/jbc.274.36.25481","article-title":"Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356","volume":"274","author":"Jensen","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0250","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.yexcr.2005.04.021","article-title":"Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation","volume":"308","author":"Benussi","year":"2005","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.bcp.2017.01.017_b0255","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0896-6273(00)80250-0","article-title":"Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A","volume":"17","author":"Sontag","year":"1996","journal-title":"Neuron"},{"issue":"34","key":"10.1016\/j.bcp.2017.01.017_b0260","doi-asserted-by":"crossref","first-page":"21901","DOI":"10.1074\/jbc.273.34.21901","article-title":"Protein phosphatase 1 is targeted to microtubules by the microtubule-associated protein Tau","volume":"273","author":"Liao","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0265","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s13167-010-0036-z","article-title":"Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy","volume":"1","author":"Mandel","year":"2010","journal-title":"EPMA J."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0270","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tibtech.2010.09.007","article-title":"Identifying and validating biomarkers for Alzheimer's disease","volume":"29","author":"Humpel","year":"2011","journal-title":"Trends Biotechnol."},{"issue":"Pt 5","key":"10.1016\/j.bcp.2017.01.017_b0275","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1258\/0004563001899898","article-title":"Genetic and biochemical markers for Alzheimer's disease: recent developments","volume":"37","author":"Mulder","year":"2000","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.bcp.2017.01.017_b0280","first-page":"143","article-title":"Overview of the genetics of parkinsonism","volume":"91","author":"Gasser","year":"2003","journal-title":"Adv. Neurol."},{"issue":"10","key":"10.1016\/j.bcp.2017.01.017_b0285","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nrn2494","article-title":"Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses","volume":"9","author":"Bertram","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0290","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1745-7254.2008.00731.x","article-title":"Advances in the genetics of Parkinson's disease","volume":"29","author":"Rosner","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2017.01.017_b0295","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1002\/mds.22723","article-title":"Clinical implications of gene discovery in Parkinson's disease and parkinsonism","volume":"25","author":"Wider","year":"2010","journal-title":"Mov. Disord."},{"issue":"23","key":"10.1016\/j.bcp.2017.01.017_b0300","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJM198006053022305","article-title":"Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts)","volume":"302","author":"Glenner","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2017.01.017_b0305","first-page":"487","article-title":"Fluorescent stains, with special reference to amyloid and connective tissues","volume":"68","author":"Vassar","year":"1959","journal-title":"Arch. Pathol."},{"issue":"24","key":"10.1016\/j.bcp.2017.01.017_b0310","doi-asserted-by":"crossref","first-page":"RC189","DOI":"10.1523\/JNEUROSCI.21-24-j0004.2001","article-title":"Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease","volume":"21","author":"Agdeppa","year":"2001","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.017_b0315","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0320","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/archneur.62.2.196","article-title":"Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies","volume":"62","author":"Mathis","year":"2005","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0325","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nn1422","article-title":"19F and 1H MRI detection of amyloid beta plaques in vivo","volume":"8","author":"Higuchi","year":"2005","journal-title":"Nat. Neurosci."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0330","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ana.410380414","article-title":"Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease","volume":"38","author":"Arai","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2017.01.017_b0335","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.neuroscience.2011.03.071","article-title":"In vivo detection of amyloid \u03b2 deposition using 19F magnetic resonance imaging with a 19F-containing curcumin derivative in a mouse model of Alzheimer's disease","volume":"184","author":"Yanagisawa","year":"2011","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.bcp.2017.01.017_b0340","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3233\/JAD-131025","article-title":"Preferred features of a fluorine-19 MRI probe for amyloid detection in the brain","volume":"39","author":"Yanagisawa","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bcp.2017.01.017_b0345","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.arr.2015.12.008","article-title":"Amyloid imaging using fluorine-19 magnetic resonance imaging","volume":"30","author":"Tooyama","year":"2016","journal-title":"Ageing Res. Rev."},{"issue":"7","key":"10.1016\/j.bcp.2017.01.017_b0350","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00259-016-3359-8","article-title":"Imaging characteristic of dual-phase (18)F-florbetapir (AV-45\/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment","volume":"43","author":"Lin","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0355","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00259-015-3208-1","article-title":"Imaging \u03b2-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis","volume":"43","author":"Heurling","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0360","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","article-title":"Beta-amyloid imaging with florbetaben","volume":"3","author":"Sabri","year":"2015","journal-title":"Clin. Transl. Imaging"},{"issue":"17","key":"10.1016\/j.bcp.2017.01.017_b0365","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.286.17.2120","article-title":"Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome","volume":"286","author":"Silverman","year":"2001","journal-title":"JAMA"},{"issue":"Pt 10","key":"10.1016\/j.bcp.2017.01.017_b0370","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/brain\/awm177","article-title":"FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease","volume":"130","author":"Foster","year":"2007","journal-title":"Brain"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2017.01.017_b0375","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jns.2005.05.001","article-title":"Neuroimaging as a marker of the onset and progression of Alzheimer's disease","volume":"236","author":"Masdeu","year":"2005","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2017.01.017_b0380","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","article-title":"Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography","volume":"41","author":"Dorbala","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0385","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40336-014-0098-3","article-title":"Amyloid PET imaging: applications beyond Alzheimer's disease","volume":"3","author":"Catafau","year":"2015","journal-title":"Clin. Transl. Imaging"},{"issue":"11","key":"10.1016\/j.bcp.2017.01.017_b0390","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2967\/jnumed.115.169870","article-title":"Cardiac Amyloid Imaging with 18F-Florbetaben PET: a Pilot Study","volume":"57","author":"Law","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0395","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1474-4422(14)70252-2","article-title":"Tau imaging: early progress and future directions","volume":"14","author":"Villemagne","year":"2015","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.bcp.2017.01.017_b0400","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","article-title":"Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls","volume":"79","author":"Maruyama","year":"2013","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0405","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00259-012-2261-2","article-title":"Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology","volume":"40","author":"Harada","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"10.1016\/j.bcp.2017.01.017_b0410","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","article-title":"[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease","volume":"9","author":"Xia","year":"2013","journal-title":"Alzheimers Dement."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0415","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2967\/jnumed.115.164848","article-title":"18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease","volume":"57","author":"Harada","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"18","key":"10.1016\/j.bcp.2017.01.017_b0420","doi-asserted-by":"crossref","first-page":"7241","DOI":"10.1021\/acs.jmedchem.5b00440","article-title":"Structure-activity relationship study of heterocyclic phenylethenyl and pyridinylethenyl derivatives as tau-imaging agents that selectively detect neurofibrillary tangles in Alzheimer's disease brains","volume":"58","author":"Matsumura","year":"2015","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0425","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3233\/JPD-130247","article-title":"\u0391-synuclein imaging: a critical need for Parkinson's disease research","volume":"3","author":"Eberling","year":"2013","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.bcp.2017.01.017_b0430","article-title":"Non-amyloid PET imaging biomarkers for neurodegeneration: Focus on tau, alpha-synuclein and neuroinflammation","author":"Catafau","year":"2016","journal-title":"Curr. Alzheimer Res."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0435","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/app4010066","article-title":"Radiosynthesis and in vivo evaluation of two pet radioligands for imaging \u03b1-synuclein","volume":"4","author":"Zhang","year":"2014","journal-title":"Appl. Sci. (Basel)"},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0440","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/WNL.59.4.627","article-title":"CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects","volume":"59","author":"Buerger","year":"2002","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.bcp.2017.01.017_b0445","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/archneur.60.12.1696","article-title":"Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?","volume":"60","author":"Clark","year":"2003","journal-title":"Arch. Neurol."},{"issue":"8","key":"10.1016\/j.bcp.2017.01.017_b0450","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1212\/01.wnl.0000299905.05595.68","article-title":"Toward a plasma marker for Alzheimer disease: some progress, but still a long way to go","volume":"70","author":"Crystal","year":"2008","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.bcp.2017.01.017_b0455","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1653","article-title":"Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins","volume":"13","author":"Ray","year":"2007","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0460","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1212\/01.wnl.0000303973.71803.81","article-title":"Biochemical markers in persons with preclinical familial Alzheimer disease","volume":"71","author":"Ringman","year":"2008","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.bcp.2017.01.017_b0465","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","article-title":"Improved discrimination of AD patients using beta-amyloid(1\u201342) and tau levels in CSF","volume":"52","author":"Hulstaert","year":"1999","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.bcp.2017.01.017_b0470","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1212\/WNL.52.3.547","article-title":"CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease","volume":"52","author":"Samuels","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0475","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0304-3940(00)00767-9","article-title":"Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease","volume":"280","author":"Tapiola","year":"2000","journal-title":"Neurosci. Lett."},{"issue":"8","key":"10.1016\/j.bcp.2017.01.017_b0480","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1096\/fj.09-150359","article-title":"High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients","volume":"24","author":"Fukumoto","year":"2010","journal-title":"FASEB J."},{"issue":"5","key":"10.1016\/j.bcp.2017.01.017_b0485","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jamaneurol.2013.48","article-title":"Correlation of specific amyloid-\u03b2 oligomers with tau in cerebrospinal fluid from cognitively normal older adults","volume":"70","author":"Handoko","year":"2013","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.bcp.2017.01.017_b0490","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1523\/JNEUROSCI.1675-13.2014","article-title":"A sensitive a\u03b2 oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid","volume":"34","author":"Savage","year":"2014","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0495","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ab.2012.09.014","article-title":"Amyloid-\u03b2 oligomer detection by ELISA in cerebrospinal fluid and brain tissue","volume":"433","author":"Bruggink","year":"2013","journal-title":"Anal. Biochem."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0500","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/JAD-142136","article-title":"Amyloid-\u03b2 oligomers relate to cognitive decline in Alzheimer's disease","volume":"45","author":"Jongbloed","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0505","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3233\/JAD-2012-120211","article-title":"The load of amyloid-\u03b2 oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients","volume":"31","author":"Sancesario","year":"2012","journal-title":"J. Alzheimers Dis."},{"issue":"7","key":"10.1016\/j.bcp.2017.01.017_b0510","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1212\/WNL.54.7.1498","article-title":"Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF","volume":"54","author":"Kahle","year":"2000","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.bcp.2017.01.017_b0515","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archneur.58.3.373","article-title":"Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice","volume":"58","author":"Andreasen","year":"2001","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0520","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ana.111","article-title":"Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231","volume":"49","author":"Hampel","year":"2001","journal-title":"Ann. Neurol."},{"issue":"Pt 11","key":"10.1016\/j.bcp.2017.01.017_b0525","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1093\/brain\/awl279","article-title":"Proteome-based plasma biomarkers for Alzheimer's disease","volume":"129","author":"Hye","year":"2006","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0530","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","article-title":"Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration","volume":"213","author":"Mollenhauer","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bcp.2017.01.017_b0535","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neulet.2012.11.004","article-title":"Total CSF \u03b1-synuclein is lower in de novo Parkinson patients than in healthy subjects","volume":"532","author":"Mollenhauer","year":"2013","journal-title":"Neurosci. Lett."},{"issue":"8","key":"10.1016\/j.bcp.2017.01.017_b0540","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/mds.25772","article-title":"Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease","volume":"29","author":"Parnetti","year":"2014","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0545","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3988\/jcn.2011.7.4.215","article-title":"Elevated levels of \u03b1-synuclein oligomer in the cerebrospinal fluid of drug-na\u00efve patients with Parkinson's disease","volume":"7","author":"Park","year":"2011","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.bcp.2017.01.017_b0550","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-015-0185-3","article-title":"Phosphorylated \u03b1-synuclein in Parkinson's disease: correlation depends on disease severity","volume":"3","author":"Stewart","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"issue":"5 Suppl","key":"10.1016\/j.bcp.2017.01.017_b0555","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/j.jalz.2013.10.004","article-title":"Increased CSF \u03b1-synuclein levels in Alzheimer's disease: correlation with tau levels","volume":"10","author":"Slaets","year":"2014","journal-title":"Alzheimers Dement."},{"issue":"9","key":"10.1016\/j.bcp.2017.01.017_b0560","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1017\/S1041610215000447","article-title":"Use of CSF \u03b1-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders","volume":"27","author":"Wang","year":"2015","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.bcp.2017.01.017_b0565","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","article-title":"Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease","volume":"11","author":"Majbour","year":"2016","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0570","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejn.13056","article-title":"Oligomeric \u03b1-synuclein and \u03b2-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases","volume":"43","author":"Williams","year":"2016","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bcp.2017.01.017_b0575","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fneur.2015.00090","article-title":"The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease","volume":"6","author":"Inekci","year":"2015","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0580","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-8993(99)01092-6","article-title":"Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients","volume":"826","author":"Garlind","year":"1999","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.017_b0585","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/archneur.56.3.281","article-title":"Biomarkers of Alzheimer disease","volume":"56","author":"Growdon","year":"1999","journal-title":"Arch. Neurol."},{"issue":"10","key":"10.1016\/j.bcp.2017.01.017_b0590","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1212\/WNL.54.10.2009","article-title":"Increased CSF levels of nerve growth factor in patients with Alzheimer's disease","volume":"54","author":"Hock","year":"2000","journal-title":"Neurology"},{"issue":"3\u20134","key":"10.1016\/j.bcp.2017.01.017_b0595","first-page":"79","article-title":"Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics","volume":"21","author":"Reiber","year":"2003","journal-title":"Restor. Neurol. Neurosci."},{"issue":"11","key":"10.1016\/j.bcp.2017.01.017_b0600","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrneurol.2016.160","article-title":"Alzheimer disease: biomarkers of AD risk \u2013 the end of the road for plasma amyloid-\u03b2?","volume":"12","author":"Wood","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.bcp.2017.01.017_b0605","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1002\/hbm.22390","article-title":"Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease","volume":"35","author":"Chiu","year":"2014","journal-title":"Hum. Brain Mapp."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0610","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/alzrt163","article-title":"Plasma tau levels in Alzheimer's disease","volume":"5","author":"Zetterberg","year":"2013","journal-title":"Alzheimers Res. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2017.01.017_b0615","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/gps.4053","article-title":"The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease","volume":"29","author":"Wang","year":"2014","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0620","first-page":"99","article-title":"Tau is reduced in AD plasma and validation of employed ELISA methods","volume":"1","author":"Sparks","year":"2012","journal-title":"Am. J. Neurodegener. Dis."},{"issue":"17","key":"10.1016\/j.bcp.2017.01.017_b0625","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","article-title":"Plasma tau in Alzheimer disease","volume":"87","author":"Mattsson","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0630","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3233\/JAD-2011-101641","article-title":"Human platelets tau: a potential peripheral marker for Alzheimer's disease","volume":"25","author":"Neumann","year":"2011","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.017_b0635","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/ageing\/afr171","article-title":"Platelet immunoglobulin and amyloid precursor protein as potential peripheral biomarkers for Alzheimer's disease: findings from a pilot study","volume":"41","author":"Mukaetova-Ladinska","year":"2012","journal-title":"Age Ageing"},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0640","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/JAD-2012-120304","article-title":"Platelet tau pattern correlates with cognitive status in Alzheimer's disease","volume":"31","author":"Far\u00edas","year":"2012","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0645","first-page":"1","article-title":"Progress of \u201cCurrent Alzheimer Research\u201d and future direction","volume":"10","author":"Lahiri","year":"2013","journal-title":"Curr. Alzheimer Res."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0650","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/mds.22928","article-title":"Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment","volume":"25","author":"Duran","year":"2010","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0655","doi-asserted-by":"crossref","first-page":"e0123162","DOI":"10.1371\/journal.pone.0123162","article-title":"Decrease in plasma levels of \u03b1-synuclein is evident in patients with Parkinson's disease after elimination of heterophilic antibody interference","volume":"10","author":"Ishii","year":"2015","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.bcp.2017.01.017_b0660","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/archneurol.2010.279","article-title":"SNCA variant associated with Parkinson disease and plasma alpha-synuclein level","volume":"67","author":"Mata","year":"2010","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0665","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neulet.2010.06.009","article-title":"Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease","volume":"480","author":"Shi","year":"2010","journal-title":"Neurosci. Lett."},{"issue":"12","key":"10.1016\/j.bcp.2017.01.017_b0670","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1096\/fj.10-179192","article-title":"Phosphorylated \u03b1-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease","volume":"25","author":"Foulds","year":"2011","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.017_b0675","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neulet.2005.02.030","article-title":"Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease","volume":"381","author":"Michell","year":"2005","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0680","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0685","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12951-016-0198-5","article-title":"Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles","volume":"14","author":"Yang","year":"2016","journal-title":"J. Nanobiotechnol."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.017_b0690","doi-asserted-by":"crossref","first-page":"e0151156","DOI":"10.1371\/journal.pone.0151156","article-title":"Abnormal salivary total and oligomeric alpha-synuclein in Parkinson's disease","volume":"11","author":"Vivacqua","year":"2016","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.bcp.2017.01.017_b0695","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.febslet.2011.03.060","article-title":"Amyloid \u03b2-induced erythrocytic damage and its attenuation by carotenoids","volume":"585","author":"Nakagawa","year":"2011","journal-title":"FEBS Lett."},{"issue":"11","key":"10.1016\/j.bcp.2017.01.017_b0700","doi-asserted-by":"crossref","first-page":"e49620","DOI":"10.1371\/journal.pone.0049620","article-title":"Amyloid \u03b2 levels in human red blood cells","volume":"7","author":"Kiko","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2017.01.017_b0705","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neulet.2015.05.030","article-title":"Detection of \u03b1-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease","volume":"599","author":"Wang","year":"2015","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.017_b0710","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1021\/acschemneuro.5b00324","article-title":"Single-molecule imaging of individual amyloid protein aggregates in human biofluids","volume":"7","author":"Horrocks","year":"2016","journal-title":"ACS Chem. Neurosci."},{"issue":"11","key":"10.1016\/j.bcp.2017.01.017_b0715","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4593","article-title":"Targeting protein aggregation for the treatment of degenerative diseases","volume":"14","author":"Eisele","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.017_b0720","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrd3050","article-title":"Protein aggregation diseases: pathogenicity and therapeutic perspectives","volume":"9","author":"Aguzzi","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2017.01.017_b0725","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejmech.2016.02.049","article-title":"Amyloid cascade in Alzheimer's disease: recent advances in medicinal chemistry","volume":"113","author":"Mohamed","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2017.01.017_b0730","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1016\/j.bbagen.2013.06.029","article-title":"Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases","volume":"1830","author":"Cheng","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"12","key":"10.1016\/j.bcp.2017.01.017_b0735","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1096\/fj.04-1764com","article-title":"Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization","volume":"18","author":"De Felice","year":"2004","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.bcp.2017.01.017_b0740","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.bpj.2011.02.010","article-title":"Resveratrol inhibits the formation of multiple-layered \u03b2-sheet oligomers of the human islet amyloid polypeptide segment 22\u201327","volume":"100","author":"Jiang","year":"2011","journal-title":"Biophys. J."},{"issue":"18","key":"10.1016\/j.bcp.2017.01.017_b0745","doi-asserted-by":"crossref","first-page":"14631","DOI":"10.1074\/jbc.M111.325456","article-title":"Phenolic compounds prevent amyloid \u03b2-protein oligomerization and synaptic dysfunction by site-specific binding","volume":"287","author":"Ono","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2017.01.017_b0750","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1074\/jbc.M404751200","article-title":"Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo","volume":"280","author":"Yang","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"34","key":"10.1016\/j.bcp.2017.01.017_b0755","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1021\/acs.jpcb.6b03892","article-title":"Action of caffeine as an amyloid inhibitor in the aggregation of A\u03b216-22 peptides","volume":"120","author":"Sharma","year":"2016","journal-title":"J. Phys. Chem. B"},{"issue":"6","key":"10.1016\/j.bcp.2017.01.017_b0760","doi-asserted-by":"crossref","first-page":"e1001080","DOI":"10.1371\/journal.pbio.1001080","article-title":"Towards a pharmacophore for amyloid","volume":"9","author":"Landau","year":"2011","journal-title":"PLoS Biol."},{"issue":"17","key":"10.1016\/j.bcp.2017.01.017_b0765","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/cbic.201402430","article-title":"A cyclic KLVFF-derived peptide aggregation inhibitor induces the formation of less-toxic off-pathway amyloid-\u03b2 oligomers","volume":"15","author":"Arai","year":"2014","journal-title":"ChemBioChem"},{"key":"10.1016\/j.bcp.2017.01.017_b0770","doi-asserted-by":"crossref","first-page":"e00857","DOI":"10.7554\/eLife.00857","article-title":"Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta","volume":"2","author":"Jiang","year":"2013","journal-title":"Elife"},{"issue":"22","key":"10.1016\/j.bcp.2017.01.017_b0775","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1021\/jm301186p","article-title":"Discovery of novel inhibitors of amyloid \u03b2-peptide 1\u201342 aggregation","volume":"55","author":"L\u00f3pez","year":"2012","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0780","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3233\/JAD-2012-121108","article-title":"Gray matter atrophy associated with extrapyramidal signs in the Lewy body variant of Alzheimer's disease","volume":"32","author":"Choi","year":"2012","journal-title":"J. Alzheimers Dis."},{"issue":"9","key":"10.1016\/j.bcp.2017.01.017_b0785","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0790","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","article-title":"Can Alzheimer disease be prevented by amyloid-beta immunotherapy?","volume":"6","author":"Lemere","year":"2010","journal-title":"Nat. Rev. Neurol."},{"issue":"9634","key":"10.1016\/j.bcp.2017.01.017_b0795","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bcp.2017.01.017_b0800","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.neurobiolaging.2013.10.085","article-title":"Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult","volume":"35","author":"Rosenblum","year":"2014","journal-title":"Neurobiol. Aging"},{"issue":"9","key":"10.1016\/j.bcp.2017.01.017_b0805","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0810","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0815","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bcp.2017.01.017_b0820","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrneurol.2013.223","article-title":"Alzheimer disease therapy\u2013moving from amyloid-\u03b2 to tau","volume":"9","author":"Giacobini","year":"2013","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.bcp.2017.01.017_b0825","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archneur.60.5.729","article-title":"Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment","volume":"60","author":"Guillozet","year":"2003","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0830","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bcp.2013.12.008","article-title":"Tau-aggregation inhibitor therapy for Alzheimer's disease","volume":"88","author":"Wischik","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2017.01.017_b0835","doi-asserted-by":"crossref","first-page":"3245935","DOI":"10.1155\/2016\/3245935","article-title":"Tau-centric targets and drugs in clinical development for the treatment of Alzheimer's disease","volume":"2016","author":"Panza","year":"2016","journal-title":"Biomed. Res. Int."},{"issue":"10","key":"10.1016\/j.bcp.2017.01.017_b0840","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2174\/1567205011666141107150331","article-title":"Structure and mechanism of action of tau aggregation inhibitors","volume":"11","author":"Cisek","year":"2014","journal-title":"Curr. Alzheimer Res."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0845","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1586\/14737175.2015.995637","article-title":"Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future","volume":"15","author":"Hampel","year":"2015","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0850","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.febslet.2014.11.026","article-title":"The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios","volume":"589","author":"Wobst","year":"2015","journal-title":"FEBS Lett."},{"issue":"9","key":"10.1016\/j.bcp.2017.01.017_b0855","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1074\/jbc.M408714200","article-title":"Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins","volume":"280","author":"Taniguchi","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"4\u20135","key":"10.1016\/j.bcp.2017.01.017_b0860","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.neuropharm.2010.01.016","article-title":"Tau protein and tau aggregation inhibitors","volume":"59","author":"Bulic","year":"2010","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.bcp.2017.01.017_b0865","doi-asserted-by":"crossref","first-page":"e0117511","DOI":"10.1371\/journal.pone.0117511","article-title":"PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo","volume":"10","author":"Okuda","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2017.01.017_b0870","doi-asserted-by":"crossref","first-page":"10216","DOI":"10.1038\/ncomms10216","article-title":"Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups","volume":"6","author":"Soeda","year":"2015","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bcp.2017.01.017_b0875","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1021\/acs.molpharmaceut.6b00165","article-title":"Inhibitory RNA aptamers of tau oligomerization and their neuroprotective roles against proteotoxic stress","volume":"13","author":"Kim","year":"2016","journal-title":"Mol. Pharm."},{"issue":"46","key":"10.1016\/j.bcp.2017.01.017_b0880","doi-asserted-by":"crossref","first-page":"33081","DOI":"10.1074\/jbc.M113.494922","article-title":"Two novel Tau antibodies targeting the 396\/404 region are primarily taken up by neurons and reduce Tau protein pathology","volume":"288","author":"Gu","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"Pt 10","key":"10.1016\/j.bcp.2017.01.017_b0885","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/brain\/awu213","article-title":"Neuronal uptake of tau\/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease","volume":"137","author":"Collin","year":"2014","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.bcp.2017.01.017_b0890","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting \u03b1-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol."},{"issue":"26","key":"10.1016\/j.bcp.2017.01.017_b0895","doi-asserted-by":"crossref","first-page":"26846","DOI":"10.1074\/jbc.M403129200","article-title":"The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils","volume":"279","author":"Zhu","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"17","key":"10.1016\/j.bcp.2017.01.017_b0900","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1073\/pnas.0910723107","article-title":"EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity","volume":"107","author":"Bieschke","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"10","key":"10.1016\/j.bcp.2017.01.017_b0905","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1007\/s11064-016-1995-9","article-title":"Epigallocatechin gallate (EGCG) inhibits alpha-synuclein aggregation: a potential agent for Parkinson's disease","volume":"41","author":"Xu","year":"2016","journal-title":"Neurochem. Res."},{"issue":"8","key":"10.1016\/j.bcp.2017.01.017_b0910","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.febslet.2011.03.046","article-title":"Inhibition and disaggregation of \u03b1-synuclein oligomers by natural polyphenolic compounds","volume":"585","author":"Caruana","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2017.01.017_b0915","doi-asserted-by":"crossref","first-page":"392169","DOI":"10.1155\/2015\/392169","article-title":"Resveratrol: a focus on several neurodegenerative diseases","volume":"2015","author":"Tellone","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.bcp.2017.01.017_b0920","doi-asserted-by":"crossref","first-page":"28511","DOI":"10.1038\/srep28511","article-title":"Effect of curcumin analogs on\u03b1-synuclein aggregation and cytotoxicity","volume":"6","author":"Jha","year":"2016","journal-title":"Sci. Rep."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2017.01.017_b0925","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jnc.13750","article-title":"Current and experimental treatments of Parkinson disease: a guide for neuroscientists","volume":"139","author":"Oertel","year":"2016","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.bcp.2017.01.017_b0930","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","article-title":"Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease","volume":"125","author":"Wagner","year":"2013","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.bcp.2017.01.017_b0935","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00401-014-1265-3","article-title":"The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset","volume":"127","author":"Levin","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"11","key":"10.1016\/j.bcp.2017.01.017_b0940","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1096\/fj.03-1346fje","article-title":"A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders","volume":"18","author":"El-Agnaf","year":"2004","journal-title":"FASEB J."},{"issue":"25","key":"10.1016\/j.bcp.2017.01.017_b0945","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.1021\/ja075356q","article-title":"Design of an N-methylated peptide inhibitor of alpha-synuclein aggregation guided by solid-state NMR","volume":"130","author":"Madine","year":"2008","journal-title":"J. Am. Chem. Soc."},{"issue":"12","key":"10.1016\/j.bcp.2017.01.017_b0950","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1074\/jbc.M114.620484","article-title":"Intracellular screening of a peptide library to derive a potent peptide inhibitor of \u03b1-synuclein aggregation","volume":"290","author":"Cheruvara","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.017_b0955","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2174\/0929866522666150209142649","article-title":"Peptides as modulators of \u03b1-synuclein aggregation","volume":"22","author":"Ruzza","year":"2015","journal-title":"Protein Pept. Lett."},{"issue":"7","key":"10.1016\/j.bcp.2017.01.017_b0960","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/14656566.2016.1149163","article-title":"New and emerging medical therapies in Parkinson's disease","volume":"17","author":"Lotia","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.bcp.2017.01.017_b0965","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0970","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40478-016-0357-9","article-title":"Novel antibodies to phosphorylated \u03b1-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes","volume":"4","author":"Rutherford","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.017_b0975","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JPD-160779","article-title":"Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: what have we learned in the last decade?","volume":"6","author":"Oueslati","year":"2016","journal-title":"J. Parkinsons Dis."},{"issue":"24","key":"10.1016\/j.bcp.2017.01.017_b0980","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"Pt B","key":"10.1016\/j.bcp.2017.01.017_b0985","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.brainres.2016.03.044","article-title":"Protein aggregation and ER stress","volume":"1648","author":"Ogen-Shtern","year":"2016","journal-title":"Brain Res."},{"issue":"111","key":"10.1016\/j.bcp.2017.01.017_b0990","doi-asserted-by":"crossref","first-page":"111cm33","DOI":"10.1126\/scitranslmed.3002609","article-title":"Testing the right target and right drug at the right stage","volume":"3","author":"Sperling","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"Pt 5","key":"10.1016\/j.bcp.2017.01.017_b0995","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/aww042","article-title":"Rifampicin is a candidate preventive medicine against amyloid-\u03b2 and tau oligomers","volume":"139","author":"Umeda","year":"2016","journal-title":"Brain"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217300473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217300473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T05:11:57Z","timestamp":1719033117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295217300473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":199,"alternative-id":["S0006295217300473"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2017.01.017","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2017.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}